Drug Delivery Report

Brooks Adams BA, MBA, Strategic Project Planning, Philip Morris USA

Brooks Adams has recently transitioned within Philip Morris USA into Strategic Product Planning. He was previously responsible for directing the commercialisation plans for Chrysalis' proprietary pulmonary drug delivery aerosol technology. Prior to joining Chrysalis, Brooks worked in business development, sales and marketing roles in biotechnology and genomics. He is skilled in evaluating growth opportunities; strategic marketing and consultative platform selling; and leading new product launches. Brooks received an MBA from the Fuqua School of Business, Duke University, and a B.A. from Davidson College. He is also a Chartered Financial Analyst. 

 Woody Bryan, PhD, Vice President of Business Development, Supernus Pharmaceuticals

Woody currently serves as Vice President of Business Development for Supernus Pharmaceuticals, formerly Shire Laboratories, the Advanced Drug Delivery Division of Shire Pharmaceuticals Group. Woody joined Shire in January 2000 where he currently serves as Vice President Business Development for Shire Laboratories, the Advanced Drug Delivery Division of Shire Pharmaceuticals Group, based in Rockville, Maryland. Dr Bryan's responsibilities at Shire include business development and licensing for Shire's bioavailability enhancement and oral controlled release drug delivery technologies. 

 J. Alejandro Donoso, PhD, sanofi-aventis corporation

J. Alejandro Donoso is with the Alliances & Partnerships group in the new sanofi-aventis corporation. He was Director of Technology Licensing & Alliances for Corporate Development at Aventis Pharmaceuticals, Inc. He has 17 years of experience in the pharmaceutical industry, from Sales and Marketing, Research and Development to Corporate Development, and has extensive experience and knowledge in scientific competitive information analysis supporting licensing, business development, marketing, research and drug discovery activities. Dr Donoso is responsible for managing the identification, evaluation and negotiation of in- and out-licensing opportunities to meet company licensing needs. Dr Donoso has an understanding of neuroscience, immunology and drug delivery technology licensing needs, and has been active in executing agreements for sponsored research to support discovery and preclinical research. 

 Dr Janet A Halliday BSc, MRPharmS, PhD, Research and Development Director, Controlled Therapeutics Ltd

Dr Halliday joined CT as a bench formulation scientist initially working on solid dosage forms before working on Cervidil. Janet was involved in FDA audits and partnership visits with Forest, Ferring and Zeneca. She has since worked on development projects both in partnership with other companies (Fisons, PowderJect, Britannia) and on CT-led hydrogel projects. Dr Halliday is now responsible for directing work leading to new IP on transmucosal delivery, new polymers and new loading approaches as well as being involved in examining both in- and out-licensing opportunities. Janet is currently an elected member of RPSGB Industrial Pharmacist Group committee and a member of Academy of Pharmaceutical Sciences and Controlled Release Society. 

 Michael Hite, Senior Formulator & Technical Writer, SCOLR Pharma, Inc.

Michael joined SCOLR Pharma in 2000 as a formulator and is one of the founding members of the Company's product development group. He is a graduate of Amherst College and is a member of the American Association of Pharmaceutical Scientists (AAPS), the Controlled Release Society (CRS), and the American Chemical Society (ACS). Michael has published multiple articles in peer-reviewed journals, presented numerous poster presentations at the AAPS and CRS national conferences, and is a frequent editorial contributor to numerous pharmaceutical industry publications. 

 Ravi Kiron, PhD, MBA, Executive Director, New Technology Assessment & Planning, Alza Corporation (a division of Johnson & Johnson)

Dr Ravi Kiron recently joined Alza Corporation as an Executive Director for New Technology Assessment and Planning. He will be a member of Alza's Executive Committee. Dr Kiron is an experienced pharmaceutical industry scientist and strategic analyst with significant experience in management, leadership and problem solving. He has diverse experience and a broad perspective of the various processes of pharmaceutical drug discovery, pre-clinical and early clinical drug development, project management, external technology investments and analysis, Mergers & Acquisitions, compound request management, database development and information protection and planning, knowledge and alliance management including in- and out-licensing for drug discovery and information technology needs. 

 Richard Korsmeyer, Director, Technology Assessment, Pfizer Global Research & Development

Richard Korsmeyer initially worked on the development of oral drug delivery technology at Pfizer before taking a management role as leader of the Oral Controlled Release Group. In his current role, he is responsible for managing a group that systematically evaluates technology for potential applicability to drug development, and works with technology companies to put agreements in place and to manage joint development projects. He is also responsible for supporting evaluations of product licensing opportunities and due diligence evaluations. He has published in serveral areas, including drug delivery, and holds a number of patents. His current professional associations include the American Association of Pharmaceutical Scientists and the Controlled Release Society. He received his MS and PhD in Chemical Engineering from Purdue University. 

 Philip Brown, PhD, MBA, Commercial Analyst, Vectura Group plc

Philip joined Vectura in December 2005. Philip works within the commercial and business development team undertaking research and analysis to support strategic decisions for Vectura. From 2001 to 2005 Philip worked in PharmaVentures consultancy where he was involved in a number of client-based consultancy projects involving aspects of strategy development, technical and commercial due diligence and licensing for drug delivery, biotech and pharmaceutical companies. He has published a number of articles relating to scientific reseach. Further publications include a review, book chapter and a textbook aimed at university students. He is also a regular contributor to the DDR and PharmaDeals Review. 

 Steven Sanders PhD, Vice President, R&D, Aveva DDS, Inc.

Dr Steven Sanders leads the development of Aveva DDS' pipeline of transdermal products. His 20+ years of experience in clinical research and specialty product development contributes to Aveva's ability to leverage the technology available from their parent company, Nitto Denko, as well as providing synergistic support for partner companies in their efforts for improved drug delivery. Dr. Sander's interests center on maximizing therapeutic effectiveness of drug compounds by applying innovative drug delivery technologies 

 Mel Hemamda, Business Development Manager, PharmaVentures Ltd

Mel joined PharmaVentures' strategic intelligence team in 2003 managing a portfolio of drug delivery products and services. Since joining the Consultancy Group in 2005, Mel has worked on a number of transaction based consultancy projects involving licensing and strategy development